From 1.5% to 5.9%: Deloitte digs into what’s fueling Big Pharma’s R&D IRR climb
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
Deloitte has examined the factors driving an increase in big pharma's research and development internal rate of return. The increase is reported to be from 1.5% to 5.9%. The specifics of what is fueling this climb are being explored by Deloitte.